Table 2.
Summary of semiquantitative analysis (maximum SUV) in individual patients
| Patient | FDG/FTT (Lesion Site #1) | FDG/FTT (Lesion #2) | FDG/FTT (Lesion #3) | FDG/FTT (Lesion #4) | FDG/FTT (Lesion #5) |
|---|---|---|---|---|---|
| 1 |
4.3/7.1 (Acetabulum) |
4.3/7.7 (Pelvic LN) |
1.8/4.6 (Retroperitoneal LN) |
3.1/5.4 (L4) |
5.1/7.1 (Prostate) |
| 2 |
8.3/8.1 (Prostate) |
12.9/6.3 (Hepatic) |
10.9/4 (iliac) |
6.4/4.6 (Ischium) |
4.3/2.3 (Pubis) |
| 3 (BRCA2) |
13.6/8.1 (Femur) |
5.2/8.2 (Ilium) |
6.3/9.1 (L5) |
4.0/6.3 (Sacrum) |
1.9/4.3 (Supraclavicular LN) |
| 4 |
3.5/9.9 (Paracaval LN) |
4.3/3.9 (Common Iliac LN) |
2.8/14.2 (Pre-Rectal LN) |
3.9/5.5 (Internal Iliac LN) |
3.5/3.6 (Para-aortic LN) |
|
5 (ÂTM) |
6.3/5.6 Inguinal LN) |
43.2/2.6 (Prostate) |
9.9/6.5 (Obturator LN) |
3.2/8.0 (Para-aortic LN) |
2.8/7.9 (Supraclavicular LN) |
|
6 (ATM, CDK12) |
9.1/7.2 (Sternal/Para-sternal soft tissue) |
2.6/6.1 (Prostate) |
1.2/7.3 External Iliac LN) |
1.4/7.8 (Prevascular) |
0.7/4.2 (Obturator LN) |
| 7 (BRCA2) |
8/13.9 (Perirectal LN) |
21.1/12 (Retroperitoneal LN) |
9.4/7.8 (Parasternal) |
27.8/12.9 (Pericardial LN) |
8.6/8.7 (Hepatic) |
| 8 (BRCA2) |
16.6/12.4 Prostate |
15.1/10.2 L5 |
2.4/15.4 Humerus |
4/12.3 Ischium |
16.3/14.9 Spinous process |
|
9 (BRCA2) |
9.8/14.9 Adrenal |
5.9/7.1 Sternum |
8/9.4 T3 |
13.4/10.2 Humerus |
6.8/7.8 Sacrum |
LN lymph node